Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P54577

UPID:
SYYC_HUMAN

ALTERNATIVE NAMES:
Tyrosyl-tRNA synthetase

ALTERNATIVE UPACC:
P54577; B3KWK4; D3DPQ4; O43276; Q53EN1

BACKGROUND:
The cytoplasmic Tyrosine--tRNA ligase, or Tyrosyl-tRNA synthetase, is essential for protein biosynthesis, ensuring the proper addition of tyrosine to tRNA(Tyr). This enzyme also independently regulates nuclear poly-ADP-ribosylation, a critical process for maintaining genomic stability. Its unique ability to switch functions upon binding with resveratrol, from promoting protein synthesis to enhancing DNA repair activities, positions it as a key player in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Tyrosine--tRNA ligase could open doors to potential therapeutic strategies. Its involvement in diseases such as Charcot-Marie-Tooth disease and multisystem infantile-onset disorders underscores its significance in neurologic and systemic pathologies, offering a promising avenue for the development of targeted treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.